A recombinant antibody-targeted plasminogen activator with high affinity for activated platelets increases thrombolytic potency in vitro and in vivo

Thrombosis Research

Volumn 97, Issue 3, 2000, Pages 133-141

  Wan, Haiying ^a   Liu, Zhenghui ^a   Xia, Xiaobo ^a   Gu, Jinming ^a   Wang, Bin ^a   Liu, Xiaojian ^a   Zhu, Mingqing ^a   Li, Peixia ^a   Ruan, Changgeng ^a  

^a The First Affiliated Hospital   (China)

Author keywords

Activated platelets; Fusion protein; Gene expression; Monoclonal antibody; Single chain urokinase; Targetting thrombolysis

Indexed keywords

HYBRID PROTEIN; MONOCLONAL ANTIBODY; PROUROKINASE; RECOMBINANT PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOENGINEERING; BLOOD CLOT LYSIS; CONTROLLED STUDY; GENE EXPRESSION; HAMSTER; HUMAN; HUMAN CELL; LUNG EMBOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; THROMBOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; BLOOD COAGULATION; BLOOD PLATELETS; CRICETINAE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBRIN; FIBRINOLYTIC AGENTS; GENETIC VECTORS; HUMANS; IODINE RADIOISOTOPES; MICE; P-SELECTIN; PLATELET ACTIVATION; PROTEIN ENGINEERING; PULMONARY EMBOLISM; RECOMBINANT FUSION PROTEINS; THROMBOLYTIC THERAPY; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033955878     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00142-5     Document Type: Article

References (28)

1. DeWood M.A., Spores J., Notske R., Mouser L.T., Burroughs R., Golden M.S., Lang H.T. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 303:1980;897-902.
2. Study Group I.M.I. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings N Engl J Med. 312:1985;932-936.
3. Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet. 1:1989;863-868.
4. GISSI-2. A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction Lancet. 336:1990;65-71.
5. GUSTO trial results American federation of clinical research. Clin Res. 41:1993;207-208.
6. ISIS-3. A randomized comparison of steptokinase vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction Lancet. 339:1992;753-770.
7. Huber K., Maurer G. Thrombolytic therapy in acute myocardial infarction. Thromb Haemostas. 22:1996;15-26.
8. De Bono D. Complications of thrombolytic therapy. Fibrinolysis. 9(Suppl. 1):1995;78-80.
9. Grünewald M., Seifried E. Meta-analysis of all available published clinical trials (1958-1990) on thrombolytic therapy for AMI. Relative efficacy of different therapeutic strategies Fibrinolysis. 8:1994;67-86.
10. Coller B.S. Seminars in medicine of the Beth Israel Hospital, Boston. Platelets and thrombolytic therapy N Engl J Med. 322:1990;33-42.
11. Bode C., Meinhardt G., Runge M.S., Freitag M., Nordt T., Arens M., Newell J.B., Kübler W., Haber E. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation. 84:1991;805-813.
12. Wu G.X., Xi X.D., Li P.X., Chu X.H., Ruan C.G. Preparation of a monoclonal antibody, SZ-51, that recognizes an a-granule membrane protein (GMP-140) on the surface of activated human platelets. Nouv Rev Fr Hematol. 32:1990;231-235.
13. Wu J.C., He G.R., Wu G.X., Ruan C.G. Radioimmunoimaging of experimental arterial and venous thrombi in dogs with 99mTc-labeled monoclonal anti-activated platelet antibody SZ51. Nucl Med Commun. 14:1993;1088-1092.
14. Gu J.M., Liu Y., Xia L.J., Wan H.Y., Li P.X., Zhang X.M., Ruan C.G. Construction and expression of mouse-human chimeric antibody SZ51 specific for activated platelet P-selectin. Thromb Haemostas. 77:1997;755-759.
15. Du L., Yu R.R., Hua Z.C., Zhu D.X., Wu G.X., Ruan C.G. Fibrinolytic effect of a chemical conjugate composed of anti-activated human platelets monoclonal antibody and urokinase. Sci China (Series B). 23:1993;32-37.
16. Ruan C.G., Du X.P., Xi X.D., Castaldi P.A., Berndt M.C. A murine antiglycoprotein Ib complex monoclonal antibody, SZ-2, inhibits platelet aggregation induced by both ristocetin and collagen. Blood. 69:1987;570-577.
17. Sanger F., Nicklen S., Coulson A.R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 74:1977;5463-5467.
18. Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., Struhl K. Short protocols in molecular biology. 1992;John Wiley & Sons, Inc, New York.
19. Han S.W., Yu W.Y., Li X.Z., Tang H.D., Fang J.M., Huang C.F. Study of the culture cell secretion blood plasminogen activator. J Chinese Academy of Military Medical Science. 2:1987;101-107.
20. Fraker P.J., Speck L.C. Protein and cell membrane iodinations with a sparingly soluble lechloroamide, 1,3,4,6-tetrachloro-3a,6a-dipheni-glycoluril dipheniglycoluril. Biochem Biophys Res Commun. 80:1978;849-857.
21. Stassen J.M., Lijnen H.R., Kieckens L., Collen D. Small animal thrombosis models for the evaluation of thrombolytic agents. Circulation. 83(Suppl. IV):1991;65-72.
22. Witt W., Maass B., Baldus B. Coronary thrombolysis with desmodus salivary plasminogen activator in dogs - Fast and persistent recanalization by intravenous bolus administration. Circulation. 90:1994;421-426.
23. Gulba D.C., Praus M., Dechend R., Hauck S., Mahler M., Zitvz R., Baldus B., Iler W M., Dietz R. Update on the toxicology and pharmacology of rDSPA alpha 1(Bat-PA) in animals and humans. Fibrinolysis & Proteolysis. 11(Suppl. 2):1997;55-62.
24. Vanderschueren S., Van de Werf F., Collen D. Recombinant staphylokinase for thrombolytic therapy. Fibrinolysis & Proteolysis. 11(Suppl. 2):1997;39-44.
25. Collen D., Stassen J.M., Yasuda T., Refino C., Paoni N., Keyt B., Roskams T., Guerrero J.L., Lijnen H.R., Gold H.K., Bennett W.F. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor resistant glycosylation variant in a combined arterial and venous thrombosis model in the dog. Thromb Haemostas. 72:1994;98-104.
26. Keyt Bpaoni N.F., Refino C.J., Berleau L., Nguyen H., Chow A., Lai J., Pena L., Pater C., Ogez J., Etcheverry T., Botstein D., Bennett W.F. A faster acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA. 91:1994;3670-3674.
27. Runge M.S., Bode C., Matsueda G.R., Haber E. Antibody-enhanced thrombolysis. Targeting of tissue plasminogen activator in vivo Proc Natl Acad Sci USA. 84:1987;7659-7662.
28. Runge M.S., Harker L.A., Bode C. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation. 94:1996;1412-1422.